The main research field of our group is pharmacoepidemiology and pharmacovigilance, with a special focus on the patterns of medicines utilization, effectiveness and adverse effects in real world. The group is a Special Group of Research recognized by AGAUR GenCat, and is a partner of the European Consortium “EU PE&PV Network”. The group together with the Preventive medicine group has become a member of the VAccine monitoring Collaboration for Europe network for the study the safety and efficacy of vaccines in Europe. We focused our interest on advanced therapies and, we continued with the project aimed to evaluate late side effects in patients treated with CAR-T cell therapy. The group has initiated its participation in the “Genomics of COVID-19 vaccine-induced GBS, VITT/TTS and miocarditis/pericarditis” project. Our group has continued the international training activities through its participation in the European master of pharmacoepidemiology and hosting fellow researchers.

Group Leader
Maria Antònia Agustí Escasany

Principal Investigator (PI)
Immaculada Danés Carreras, Glòria Cereza García, Mònica Sabaté Gallego

Researchers
Xavier Vidal Guitart, Cristina Aguilera Martín, Montserrat Bosch Ferrer, Núria García Doladé, Carmen Asensio Ostos, Eulàlia Pérez Esquirol, Elena Ballarín Alins, Eduard Diogène Fadini, Lourdes Vendrell Bosch, Angela Mesas Idáñez, Francisco Javier Medel Lina Camacho Arteaga

PhD Students
Carla Sans Pola, Judit Riera Arnau, Carolina Iglesias López, Krsitopher Amaro Hosey, Lina Leguizamo, Gustavo Molina Molina, Elena Guillen Benitez, Emilie Anderssen Nordalh, Manuel Machado Duque, Lucía Bellas Fernández

Nursing and Technical Staff
Jose J. Barroso, Montserrat Pérez González

21

PUBLICATIONS

33.3%

%Q1

108

IMPACT FACTOR

5.17

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Ön BI , Vidal X, Berger U, Sabaté M, Ballarín E, Maisterra O, San-José A, Ibáñez L.
Antidepressant use and stroke or mortality risk in the elderly.
Eur J Neurol. 2022; 29(2):469-477
DOI: doi: 10.1111/ene.15137
IF: 6.29

Camacho-Arteaga LF, Gardarsdottir H, Ibañez L, Souverein PC, van Dijk L, Hek K, Vidal X, Ballarín E, Sabaté M.
Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database.
J Affect Disord. 2022; 303:131-137.
DOI: doi: 10.1016/j.jad.2022.02.001
IF: 6.53

García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, de la Torre-Tarazona HE, Arribas J-R, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group.
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
EClinicalMedicine. 2022; 50:101529.
DOI: doi: 10.1016/j.eclinm.2022.101529
IF: 17.03

Server A, Suso-Ribera C, Pérez-Carrasco M, Medel J, Mesas A, Ayora A, Gracia RM.
Feasibility of a brief mindfulness-based program for burnout in pain healthcare professionals.
Front Psychol. 2022; 13:1009266.
DOI: doi: 10.3389/fpsyg.2022.1009266
IF: 4.23

Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, Vidal Guitart X, Carreras Soler M-J, Farriols Danés A, Felip E, Braña I, Galceran JC, Morales Barrera R, Muñoz-Couselo E, Agustí Escasany A.
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
Front Med. 2022; 9:891179
DOI: doi: 10.3389/fmed.2022.891179
IF: 5.06

A phase IIb, double-blind, randomized, active controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein rbd fusion dimer candidate (PHH-1V) against sars-cov-2 in adults fully vaccinated against covid-19.
Principal Investigator: Susana Otero
Agency: Hipra Scientific, s.l.u.
Funding: 200,620.8 €
Period: 2021-2022

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomized, controlled, phase 2 trial.
Principal Investigator: Magdalena Campins.
Agency: Instituto de Salut Carlos III
Funding: -
Period: 2021-2022

Detection of false positives in patients with an electronic beta-lactam allergy alert in their medical records
Principal Investigator: Victòria Cardona Dahl
Agency: ISCIII-FIS
Funding: 36,330 €
Period: 2020-2022

COVID-19 infection and medicines in pregnancy – a multinational registry based study Medication use in pregnant women with COVID-19 (EMA/2018/28PE No4).
Principal Investigator: Olaf Klungel, Miriam Sturkenboom (UU, UMC), Hedvig Nordeng (UO).
Agency: European Medicines Agency (EMA)
Funding: 548,890€, allocated budget: 25,000€.
Period: 2020-2022

Genomics of COVID-19 vaccine-induced GBS, VITT/TTS and miocarditis/pericarditis
Principal Investigator: Xavier Martínez and Mònica Sabaté
Agency: VAC4EU
Funding: 10,000$+3,000$+100$case+20$control
Period: 2022-2024

eCOREs